Anti p4hb

To verify the significance and potential mechanism of the risk signature, we analyzed immunohistochemical (IHC) protein staining data of CD133, P4HB, IBA1 and CD163 in the glioma samples from CGGA dataset. The IHC expression levels were compared in the low-, medium- and high-risk score groups with a nonparametric test. Briefly, five-micrometer-thick sections were deparaffinized, boiled with EDTA antigen retrieval buffer, and then incubated with the primary antibodies overnight at 4 °C (anti-CD133 antibody, 1:1000 dilution, Proteintech Group; anti-P4HB, 1:1000, Abcam; anti-IBA1, 1:2000, Abcam; anti-CD163, 1:200, Abcam). Then, the sections were incubated with appropriate secondary antibodies (1:100, ZSGB-Bio, Beijing, China) at room temperature for 1 h. Finally, the stained slides were individually reviewed and evaluated by two investigators. The expression levels of each protein in tumor tissues were defined as the portion of positively stained cells against total counted cells. The difference was assessed by Student-t test.